BTK and diffuse large B-cell lymphoma: Synergistic antiproliferative effects were also observed with OTX015 when tested over a panel of five DLBCL cell lines in combination with either mTOR, PI3K-delta, or BTK inhibitors (everolimus, idelalisib, and ibutrinib respectively), immunomodulatory drugs (IMiDs, lenanidomide), DNA methyltransferase inhibitor (decitabine), chemotherapy agents (doxorubicin and bendamustine), or the anti-CD20 targeting antibody rituximab [76].